Substituted quinolineins used as improved inhibitors of NF-κB (NIK)-inducing kinase

Abstract

<pre>The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as NF-κB (NIK)-inducing kinase inhibitors and, in particular, can induce the intracellular degradation of NIK, making these compounds highly advantageous for use in therapy, including for the treatment or prevention of cancer, inflammatory diseases, and autoimmune diseases.< / pre>